Analyst Forecasts Near-Triple-Digit Upside for Viking Therapeutics Stock
Published on 12/21/2025 at 07:14 | Redaktion boerse-global.de
A prominent analyst at investment bank H.C. Wainwright has reiterated a bullish stance on Viking Therapeutics, setting a price target that suggests massive potential gains for the biotech firm’s shares. The optimism stems not from new internal data, but rather from positive clinical developments reported by a major industry competitor, Eli Lilly.
Joseph Pantginis, an analyst at H.C. Wainwright, recently reaffirmed his “Buy” rating for Viking Therapeutics. He maintained a price objective of $102 per share. With the stock closing at $35.19 this past Friday, this target implies an upside of approximately 190 percent.
The catalyst for this renewed confidence emerged from Eli Lilly’s latest long-term data Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
